| Expression pattern: |
UP |
| Associated gene: |
caspase-3 |
| Associated microRNA: |
miR-182-5p |
| Biological function: |
Promotes cisplatin resistance and GC cell viability, inhibits apoptosis, and is associated with aggressive biological behavior in GC patients treated with CDDP. |
| Molecular mechanism: |
circFN1 acts as a ceRNA by sponging miR-182-5p, thereby inhibiting miR-182-5p-mediated activation of apoptosis via the caspase-3 signaling pathway and facilitating CDDP resistance. |
| Biological pathway or process: |
apoptosis (inhibits); proliferation (promotes); chemoresistance (promotes); drug resistance (promotes); ceRNA regulation (other) |
| Detected method: |
Q
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; RT-qPCR; RNA-seq; FISH / smFISH; Clinical Sample Validation; RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; TUNEL; Western Blot; In Vivo Animal Model; Bioinformatics Analysis |
| Clinical significance: |
CircFN1 upregulation in GC patients treated with CDDP was significantly correlated with aggressive biological behavior, CDDP resistance, clinical stage, and T classification; circFN1 is implicated as a therapeutic target for GC patients treated with CDDP. |
| Description: |
circFN1 is up-regulated in cisplatin-resistant gastric cancer tissues and cell lines. It promotes CDDP resistance by acting as a ceRNA sponge for miR-182-5p, reducing apoptosis through the caspase-3 signaling pathway and enhancing cell viability and tumor growth under cisplatin treatment. Clinically, higher circFN1 expression is associated with CDDP resistance and more aggressive clinicopathological features. |
| Confidence score: |
0.8206 |